Loading...
Cardio Diagnostics Holdings, Inc.
CDIO•NASDAQ
HealthcareBiotechnology
$0.19
$-0.03(-12.85%)
Cardio Diagnostics Holdings, Inc. (CDIO) Stock Overview
Explore Cardio Diagnostics Holdings, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for CDIOStats details for CDIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CDIOAnalyst Recommendations details for CDIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
CEO
Dr. Meeshanthini V. Dogan Ph.D.
Employees
13
Headquarters
400 N Aberdeen St, Chicago, IL
Founded
2022